BR112018005969A2 - inibidor de alquinil piridina prolil hidroxilase e método de preparação e uso médico do mesmo - Google Patents
inibidor de alquinil piridina prolil hidroxilase e método de preparação e uso médico do mesmoInfo
- Publication number
- BR112018005969A2 BR112018005969A2 BR112018005969-2A BR112018005969A BR112018005969A2 BR 112018005969 A2 BR112018005969 A2 BR 112018005969A2 BR 112018005969 A BR112018005969 A BR 112018005969A BR 112018005969 A2 BR112018005969 A2 BR 112018005969A2
- Authority
- BR
- Brazil
- Prior art keywords
- prolyl hydroxylase
- present
- preparation
- medical use
- hydroxylase inhibitor
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 2
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 title abstract 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N pyridine Substances C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 title abstract 2
- 229940078467 Prolyl hydroxylase inhibitor Drugs 0.000 title 1
- -1 alkynyl pyridine Chemical compound 0.000 title 1
- 208000007502 anemia Diseases 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 102000003951 Erythropoietin Human genes 0.000 abstract 1
- 108090000394 Erythropoietin Proteins 0.000 abstract 1
- 102000008109 Mixed Function Oxygenases Human genes 0.000 abstract 1
- 108010074633 Mixed Function Oxygenases Proteins 0.000 abstract 1
- 102000004079 Prolyl Hydroxylases Human genes 0.000 abstract 1
- 108010043005 Prolyl Hydroxylases Proteins 0.000 abstract 1
- 208000020832 chronic kidney disease Diseases 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 229940105423 erythropoietin Drugs 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 208000023589 ischemic disease Diseases 0.000 abstract 1
- 208000031225 myocardial ischemia Diseases 0.000 abstract 1
- OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 230000028327 secretion Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/81—Amides; Imides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/443—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyridine Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510648342.9A CN105130888A (zh) | 2015-10-09 | 2015-10-09 | 炔基吡啶类脯氨酰羟化酶抑制剂、其制备方法和医药用途 |
| CN201510648342.9 | 2015-10-09 | ||
| PCT/CN2015/095728 WO2017059623A1 (zh) | 2015-10-09 | 2015-11-27 | 炔基吡啶类脯氨酰羟化酶抑制剂、其制备方法和医药用途 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112018005969A2 true BR112018005969A2 (pt) | 2018-10-16 |
Family
ID=54716523
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112018005969-2A BR112018005969A2 (pt) | 2015-10-09 | 2015-11-27 | inibidor de alquinil piridina prolil hidroxilase e método de preparação e uso médico do mesmo |
Country Status (20)
| Country | Link |
|---|---|
| US (2) | US10889546B2 (https=) |
| EP (1) | EP3360862B1 (https=) |
| JP (1) | JP6635562B2 (https=) |
| KR (1) | KR20180063229A (https=) |
| CN (2) | CN105130888A (https=) |
| AU (1) | AU2015411258B2 (https=) |
| BR (1) | BR112018005969A2 (https=) |
| CA (1) | CA3000040A1 (https=) |
| DK (1) | DK3360862T3 (https=) |
| ES (1) | ES2794002T3 (https=) |
| HR (1) | HRP20200907T1 (https=) |
| HU (1) | HUE049409T2 (https=) |
| LT (1) | LT3360862T (https=) |
| MX (1) | MX379007B (https=) |
| PL (1) | PL3360862T3 (https=) |
| PT (1) | PT3360862T (https=) |
| RU (1) | RU2692494C1 (https=) |
| SI (1) | SI3360862T1 (https=) |
| UA (1) | UA120407C2 (https=) |
| WO (1) | WO2017059623A1 (https=) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105130888A (zh) * | 2015-10-09 | 2015-12-09 | 中国药科大学 | 炔基吡啶类脯氨酰羟化酶抑制剂、其制备方法和医药用途 |
| CN107417605A (zh) * | 2017-08-02 | 2017-12-01 | 江苏艾立康药业股份有限公司 | 作用于脯氨酰羟化酶的吡啶衍生化合物 |
| JP2021500315A (ja) * | 2017-10-25 | 2021-01-07 | ジエンス ヘンルイ メデイシンカンパニー リミテッドＪｉａｎｇｓｕ Ｈｅｎｇｒｕｉ Ｍｅｄｉｃｉｎｅ Ｃｏ．，Ｌｔｄ． | アルキニルピリジンプロリル水酸化酵素阻害剤の結晶型及びその製造方法 |
| CN110240562B (zh) * | 2018-03-08 | 2022-04-12 | 江苏恒瑞医药股份有限公司 | 一种脯氨酰羟化酶抑制剂的可药用盐、晶型及其制备方法 |
| CA3098564A1 (en) * | 2018-05-24 | 2019-11-28 | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | Method for preparing alkynyl pyridine prolyl hydroxylase inhibitor |
| CN109593084B (zh) * | 2019-01-23 | 2021-09-28 | 中国药科大学 | 脯氨酰羟化酶小分子光敏前药及其制备方法与应用 |
| US20220160693A1 (en) * | 2019-03-04 | 2022-05-26 | Jiangsu Hengrui Medicine Co., Ltd. | Pharmaceutical composition of prolyl hydroxylase inhibitor and preparation method therefor |
| CN116670131A (zh) * | 2020-08-14 | 2023-08-29 | 阿克比治疗有限公司 | Phd抑制剂化合物、组合物和使用方法 |
| CN112741834A (zh) * | 2021-02-07 | 2021-05-04 | 复旦大学附属中山医院 | HIF-1α降解抑制剂在制备酮体水平升高的冠心病药物中的应用 |
| CN116120340B (zh) * | 2021-11-15 | 2023-10-31 | 艾立康药业股份有限公司 | 一种吡啶并噁嗪类化合物及其制备方法、组合物和用途 |
| CN116514710B (zh) * | 2022-01-21 | 2024-07-05 | 中国药科大学 | 环取代炔基吡啶甲酰甘氨酸衍生物、制备方法、药物组合物和应用 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE4410480A1 (de) * | 1994-03-25 | 1995-09-28 | Hoechst Ag | Sulfonamidocarbonylpyridin-2-carbonsäureesteramide sowie ihre Pyridin-N-oxide, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel |
| PL3357911T3 (pl) * | 2006-06-26 | 2022-09-05 | Akebia Therapeutics Inc. | Inhibitory prolilohydroksylazy i sposoby ich użycia |
| ES2393326T3 (es) * | 2006-12-18 | 2012-12-20 | Amgen, Inc | Compuestos basados en azaquinolona que presentan actividad inhibidora de prolil hidroxilasas, composiciones y usos de los mismos |
| TW200845991A (en) * | 2007-01-12 | 2008-12-01 | Smithkline Beecham Corp | N-substituted glycine derivatives: hydroxylase inhibitors |
| TW201141839A (en) * | 2010-04-19 | 2011-12-01 | Daiichi Sankyo Co Ltd | Substituted 5-hydroxypyrimidine-4-carboxamide compounds |
| WO2012031298A2 (en) * | 2010-09-03 | 2012-03-08 | Duke University | Ethynylbenzene derivatives |
| CN104024227B8 (zh) * | 2011-07-22 | 2025-07-29 | 北京贝美拓新药研发有限公司 | 抑制脯氨酸羟化酶活性的化合物的晶型及其应用 |
| CN105130888A (zh) * | 2015-10-09 | 2015-12-09 | 中国药科大学 | 炔基吡啶类脯氨酰羟化酶抑制剂、其制备方法和医药用途 |
-
2015
- 2015-10-09 CN CN201510648342.9A patent/CN105130888A/zh active Pending
- 2015-11-27 SI SI201531228T patent/SI3360862T1/sl unknown
- 2015-11-27 HU HUE15905721A patent/HUE049409T2/hu unknown
- 2015-11-27 EP EP15905721.5A patent/EP3360862B1/en active Active
- 2015-11-27 CN CN201580079971.2A patent/CN107848976B/zh active Active
- 2015-11-27 PL PL15905721T patent/PL3360862T3/pl unknown
- 2015-11-27 JP JP2018515119A patent/JP6635562B2/ja not_active Expired - Fee Related
- 2015-11-27 HR HRP20200907TT patent/HRP20200907T1/hr unknown
- 2015-11-27 RU RU2018113258A patent/RU2692494C1/ru active
- 2015-11-27 WO PCT/CN2015/095728 patent/WO2017059623A1/zh not_active Ceased
- 2015-11-27 ES ES15905721T patent/ES2794002T3/es active Active
- 2015-11-27 AU AU2015411258A patent/AU2015411258B2/en not_active Ceased
- 2015-11-27 BR BR112018005969-2A patent/BR112018005969A2/pt not_active Application Discontinuation
- 2015-11-27 UA UAA201804628A patent/UA120407C2/uk unknown
- 2015-11-27 KR KR1020187012413A patent/KR20180063229A/ko not_active Ceased
- 2015-11-27 LT LTEP15905721.5T patent/LT3360862T/lt unknown
- 2015-11-27 PT PT159057215T patent/PT3360862T/pt unknown
- 2015-11-27 MX MX2018003832A patent/MX379007B/es unknown
- 2015-11-27 DK DK15905721.5T patent/DK3360862T3/da active
- 2015-11-27 CA CA3000040A patent/CA3000040A1/en not_active Abandoned
- 2015-11-27 US US15/765,387 patent/US10889546B2/en not_active Expired - Fee Related
-
2020
- 2020-09-11 US US17/018,221 patent/US20200407319A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| EP3360862B1 (en) | 2020-04-22 |
| KR20180063229A (ko) | 2018-06-11 |
| US20200407319A1 (en) | 2020-12-31 |
| HRP20200907T1 (hr) | 2020-09-04 |
| CN107848976B (zh) | 2020-11-17 |
| EP3360862A1 (en) | 2018-08-15 |
| CN105130888A (zh) | 2015-12-09 |
| CA3000040A1 (en) | 2017-04-13 |
| AU2015411258B2 (en) | 2020-09-17 |
| US10889546B2 (en) | 2021-01-12 |
| WO2017059623A1 (zh) | 2017-04-13 |
| AU2015411258A1 (en) | 2018-05-10 |
| RU2692494C1 (ru) | 2019-06-25 |
| ES2794002T3 (es) | 2020-11-17 |
| CN107848976A (zh) | 2018-03-27 |
| MX379007B (es) | 2025-03-11 |
| UA120407C2 (uk) | 2019-11-25 |
| PT3360862T (pt) | 2020-05-27 |
| DK3360862T3 (da) | 2020-06-02 |
| SI3360862T1 (sl) | 2020-08-31 |
| JP2018529690A (ja) | 2018-10-11 |
| HUE049409T2 (hu) | 2020-10-28 |
| EP3360862A4 (en) | 2018-08-15 |
| US20180305317A1 (en) | 2018-10-25 |
| JP6635562B2 (ja) | 2020-01-29 |
| LT3360862T (lt) | 2020-07-10 |
| HK1247613A1 (zh) | 2018-09-28 |
| MX2018003832A (es) | 2018-06-18 |
| PL3360862T3 (pl) | 2020-09-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112018005969A2 (pt) | inibidor de alquinil piridina prolil hidroxilase e método de preparação e uso médico do mesmo | |
| PH12017500367B1 (en) | Compounds that inhibit mcl-1 protein | |
| WO2017100726A8 (en) | Methods for treating huntington's disease | |
| DK3313991T3 (da) | Modificeret faktor ix og sammensætninger, fremgangsmåder og anvendelser til genoverførsel til celler, organer og væv | |
| EA201691590A1 (ru) | Бензимидазол-2-амины в качестве ингибиторов midhi | |
| PL417066A1 (pl) | Inhibitory arginazy oraz ich zastosowania terapeutyczne | |
| MX383856B (es) | Compuestos y composiciones para inhibir la actividad de shp2. | |
| MX2021009806A (es) | Ésteres de ácidos grasos de cadena media de beta-hidroxibutirato y butanodiol y composiciones y métodos para usar los mismos. | |
| WO2017075629A3 (en) | Wee 1 kinase inhibitors and methods of making and using the same | |
| EA201891191A1 (ru) | 2-замещенные соединения хиназолина, содержащие замещенную гетероциклическую группу, и способы их применения | |
| MX2016010266A (es) | Formas solidas cristalinas de n-{4-[(6,7-dimetoxiquinolin-4-il)oxi ]fenil}-n'-(4-fluorofenil)ciclopropan-1,1-dicarboxamida, procesos para elaboracion y metodos de uso. | |
| BR112016015235A2 (pt) | Composto, composição farmacêutica, método de inibição da atividade da proteína quinase erk e método de tratamento | |
| BR112016013201A2 (pt) | administração, uso e aplicações terapêuticas dos sistemas crispr-cas e composições para edição de genoma | |
| MX2016002077A (es) | Inhibidores de la proteína regulada por glucosa 94 (gpr94) selectivos y usos de los mismos. | |
| BR112014017840A8 (pt) | Compostos terapeuticamente ativos, sua composição farmacêutica e seu uso | |
| EA201491399A1 (ru) | Селективные ингибиторы cdk8/cdk19 и их применение в качестве противометастатических и химиопрофилактических агентов для лечения рака | |
| UA117103C2 (uk) | Сполука, яка має активність агоніста глюкагону | |
| MX380281B (es) | Compuestos, composiciones farmacéuticas y métodos de uso de agonistas de ppar. | |
| MX391216B (es) | Composicion farmaceutica que comprende un vector adenoviral. | |
| TN2015000574A1 (en) | Compounds and compositions as inhibitors of mek | |
| BR112019001980A2 (pt) | inibidor de ido1 e método de preparação e aplicação do mesmo | |
| MX2020011415A (es) | Metodos de usar zscan4 para rejuvenecer celulas humanas. | |
| BR112015017241A8 (pt) | composto, composição farmacêutica, uso do composto e da composição farmacêutica e kit | |
| WO2016004404A3 (en) | Gls1 inhibitors for treating disease | |
| WO2015171558A3 (en) | BENZENESULFONAMIDO AND RELATED COMPOUNDS FOR USE AS AGONISTS OF RORγ AND THE TREATEMENT OF DISEASE |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] |
Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS. |
|
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
| B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
| B06A | Patent application procedure suspended [chapter 6.1 patent gazette] | ||
| B11B | Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements |